AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NOVO RESOURCES CORP-CDI

0.115

+0.000

Volume:305.57K

Turnover:35.48K

Market Cap:40.78M

PE:-1.55

High:0.120

Open:0.115

Low:0.115

Close:0.115

Loading ...

Overview Company News Filings

Top Stock Movers Now: Amgen, Best Buy, JM Smucker, and More

Top Midday Stories: Automaker Shares Fall on New Trump Tariff Threat; Amgen Shares Tumble on Obesity Drug Study Results

MT Newswires Live

European Equities Traded in the US as American Depositary Decline in Tuesday Trading

MT Newswires Live

Sector Update: Health Care Stocks Mixed Premarket Tuesday

MT Newswires Live

Eli Lilly, Nordisk Shares up Pre-Bell on White House Proposal to Expand Medicaid, Medicare Coverage of Weight-Loss Drugs

MT Newswires Live

Update: Market Chatter: Eli Lilly, Novo Nordisk Press Employers to Cover the Cost of Weight-Loss Drugs

MT Newswires Live

White House Proposes Expanding Medicare, Medicaid Coverage for Anti-Obesity Drugs

MT Newswires Live

Novo Nordisk to Buy Norwegian Fish Genetics Firm Benchmark Genetics

MT Newswires Live

Market Chatter: Novo Holdings to Win EU Approval for $16.5 Billion Catalent Takeover

MT Newswires Live

Viking Therapeutics a new buy at B Riley on lead obesity asset VK2735

Novo Nordisk said to have contracted Ypsomed to make next gen obesity drug’s pens

European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday

MT Newswires Live

Sector Update: Health Care Stocks Edge Higher Premarket Wednesday

MT Newswires Live

Novo Resources Sells Remaining Stake in Western Australia JV; Shares Up 8%

MT Newswires Live

Novo Nordisk semaglutide phase 3 trial for MASH meets primary endpoints

Sector Update: Health Care Stocks Mixed Tuesday Afternoon

MT Newswires Live

Market Chatter: Eli Lilly, Novo Nordisk Press Employers to Cover the Cost of Weight-Loss Drugs

MT Newswires Live

Sector Update: Health Care Stocks Mixed in Afternoon Trading

MT Newswires Live

Novo Nordisk reportedly launches Wegovy in China

Top Midday Stories: Spirit Airlines Files for Chapter 11 Bankruptcy Protection; Trump Team Looking to Ease Rules for Self-Driving Cars

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NVO.AU/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVO.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVO.AU\",,,,,undefined,":{"symbol":"NVO.AU","market":"AU","secType":"STK","nameCN":"NOVO RESOURCES CORP-CDI","latestPrice":0.115,"timestamp":1745907120000,"preClose":0.115,"halted":0,"volume":305573,"delay":0,"nameEN":"NOVO RESOURCES CORP-CDI","floatShares":314709406,"shares":354630279,"eps":-0.07397144850881221,"marketStatus":"Closed","change":0,"latestTime":"04-29 16:12:00 AEST","open":0.115,"high":0.12,"low":0.115,"amount":35477,"amplitude":0.043478,"askPrice":0.115,"askSize":11646,"bidPrice":0.11,"bidSize":9050,"shortable":3,"etf":0,"ttmEps":-0.07397144850881221,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745971200000},"marketStatusCode":5,"adr":0,"adrRate":1,"listingDate":1694268000000,"exchange":"ASX","adjPreClose":0.115,"openAndCloseTimeList":[[1745884800000,1745906400000]],"volumeRatio":3.800404,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVO.AU\",,,,,undefined,":{"symbol":"NVO.AU","floatShares":314709406,"roa":"-13.14%","roe":"-30.09%","lyrEps":-0.073959,"volumeRatio":3.800404,"shares":354630279,"dividePrice":0,"high":0.12,"amplitude":0.043478,"preClose":0.115,"low":0.115,"week52Low":0.081,"pbRate":"0.52","psRate":"14.49","week52High":0.16,"institutionHeld":0,"latestPrice":0.115,"committee":-0.125435,"eps":-0.07395900773014757,"divideRate":0,"volume":305573,"delay":0,"ttmEps":-0.07395900773014757,"open":0.115,"prevYearClose":0.094,"prevWeekClose":0.12,"prevMonthClose":0.098,"prevQuarterClose":0.098,"fiveDayClose":0.1,"twentyDayClose":0.1,"sixtyDayClose":0.095},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVO.AU\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2486884898","title":"Top Stock Movers Now: Amgen, Best Buy, JM Smucker, and More","url":"https://stock-news.laohu8.com/highlight/detail?id=2486884898","media":"Investopedia","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486884898?lang=en_us&edition=fundamental","pubTime":"2024-11-27 01:03","pubTimestamp":1732640623,"startTime":"0","endTime":"0","summary":"U.S. equities were mixed at midday following comments from President-elect Trump about new tariffs on Chinese, Canadian, and Mexican imports.Results from a study of Amgen's experimental weight-loss treatment came in below expectations, sending shares sinking.J.M. Smucker raised its guidance on strong sales of its packaged and frozen foods.U.S. equities were mixed at midday as the markets weighed the potential impact of President-elect Donald Trump's plan to slap steeper tariffs on imports from China, and new ones on Canadian and Mexican products. The Dow Jones Industrial Average fell, while the S&P 500 and Nasdaq rose.Amgen  was the worst-performing stock in the Dow and S&P 500 after the biotech reported results from a study of its experimental weight-loss drug that came in below expectations.Shares of Best Buy  tumbled when the electronics retailer missed profit and revenue estimates and slashed its outlook, which it blamed on macroeconomic worries, customers waiting for deals, and th","market":"sg","thumbnail":"https://www.investopedia.com/thmb/1HUamBdeOZHPPjhN8ef6tXQ2jbE=/6000x4000/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-1491081305-af5268c668254a858ffbdff7f23ff560.jpg","type":0,"news_type":0,"thumbnails":["https://www.investopedia.com/thmb/1HUamBdeOZHPPjhN8ef6tXQ2jbE=/6000x4000/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-1491081305-af5268c668254a858ffbdff7f23ff560.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investopedia.com/top-stock-movers-now-amgen-best-buy-jm-smucker-and-more-8752087","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investopedia_highlight","symbols":["LU1093756168.USD","WMT","LU2106854487.HKD","BK4516","LU0096364046.USD","LU2324357040.USD","AMGN","LU1868837300.USD","LU2430703178.SGD","LU2552382132.HKD","LU1267930490.SGD","BBY","LU2505996681.GBP","SJM","LU1366192091.USD","LU0211328371.USD","NVO","BK4212","LU1267930730.SGD","SG9999014914.USD","STZ","IE00BFTCPJ56.SGD","IE0002141913.USD","LU2125154778.USD","LU2461242641.AUD","LU1551013425.SGD","LU0238689110.USD","LU2491050154.USD","LU1585245621.USD","LU1066051225.USD","TGT","LLY","LU0868494617.USD","LU1988902786.USD","LU0385154629.USD","LU0198837287.USD","BK4169","LU0823411888.USD","LU0943347566.SGD","LU0094547139.USD","LU2063271972.USD","SGXZ99366536.SGD","LU2237443382.USD","LU0820561818.USD","SG9999014906.USD","BK4533","LU0006306889.USD","LU1868836914.USD","NVO.AU","LU0882574139.USD"],"gpt_icon":1},{"id":"2486886480","title":"Top Midday Stories: Automaker Shares Fall on New Trump Tariff Threat; Amgen Shares Tumble on Obesity Drug Study Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2486886480","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486886480?lang=en_us&edition=fundamental","pubTime":"2024-11-27 00:57","pubTimestamp":1732640253,"startTime":"0","endTime":"0","summary":"The Nasdaq Composite and S&P 500 Index were both up in late-morning trading Tuesday, while the Dow Jones Industrial Average was down, as Wall Street assesses the potential impact of tariffs promised b","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0203201768.USD","STZ","LLY","LU1974910355.USD","LU0058720904.USD","BK4139","IE00BK4W5M84.HKD","LU0096364046.USD","NVO","LU2552382058.USD","RIVN","LU1868836914.USD","UAL","LU2237443465.HKD","LU0417517546.SGD","SG9999013999.USD","IE00BK4W5L77.USD","BK7077","GM","STLA","AAL.AU","BK4559","LU2461242641.AUD","LU2242646821.SGD","DAL.AU","ULCC","SG9999017495.SGD","NVO.AU","DAL","AMGN","LU0052756011.USD","F","LU1988902786.USD","LU0061475181.USD","LU0640476718.USD","LU2237438978.USD","LU0251131958.USD","LU1267930227.SGD","IE00BJLML261.HKD","LU0648001328.SGD","BBY","X","INTC","LU0471298694.HKD","LU2237443622.USD","LU0868494617.USD","BK4099","AAL","LU1064927863.SGD"],"gpt_icon":1},{"id":"2486868228","title":"European Equities Traded in the US as American Depositary Decline in Tuesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2486868228","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486868228?lang=en_us&edition=fundamental","pubTime":"2024-11-27 00:12","pubTimestamp":1732637525,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were moving lower late Tuesday morning, declining 0.37% to 1,317.16 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical companies DBV Technologies  and Cellectis , which climbed 14% and 4.6% respectively. They were followed by furniture maker Natuzzi  and pharmaceutical company Novo Nordisk , which rose 4.1% and 1.8% respectively.The decliners from continental Europe were led by biopharmaceutical company Genfit  and financial services company Banco Bilbao Vizcaya Argentaria , which fell 8.4% and 2.6% respectively. They were followed by petroleum refiner Equinor  and medical device maker EDAP TMS , which lost 2% each.From the UK and Ireland, the gainers were led by pharmaceutical company Silence Therapeutics  and biopharmaceutical company NuCana , which increased 6% each. They were followed  by biotech firm Autolus Therapeutics  and cruise line operator Carnival , which w","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EDAP","BK4082","BK7104","NVO.AU","BK4095","AKTX","NCNA","GNFT","BK4532","EQNR","BK4588","DBVT","BK4201","IE00BKVL7J92.USD","LU1093756168.USD","ADAP","NTZ","SLN","BK4585","IE00BZ1G4Q59.USD","BBVA","BK4599","CUK","LU0154236417.USD","AFG","NVO","TCBP","BK4107","BK4139","BK4142","AUTL","LU1093756325.SGD","BK4117","BK4007","BK4207","AMRN","CLLS"],"gpt_icon":1},{"id":"2486803006","title":"Sector Update: Health Care Stocks Mixed Premarket Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2486803006","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486803006?lang=en_us&edition=fundamental","pubTime":"2024-11-26 22:14","pubTimestamp":1732630467,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed premarket Tuesday as the Health Care Select Sector SPDR Fund  was 0.2% higher and the iShares Biotechnology ETF  was recently down 0.6%.Poseida Therapeutics  shares surged past 227% after the company said it has agreed to be acquired by Roche Holdings in a deal that has an equity value of about $1.5 billion on a fully diluted basis.Eli Lilly  shares were up over 3% and Novo Nordisk  shares over 2% higher after the White House announced a proposal to expand Medicaid and Medicare coverage to include more anti-obesity indications for the companies' popular weight loss and diabetes drugs.Amgen  said a phase 2 study showed that its investigational obesity drug MariTide caused an up to 20% average weight loss after a year in people living with obesity or overweight without type 2 diabetes without plateauing. Amgen shares fell past 11% pre-bell.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0708995401.HKD","LU0320765992.SGD","LU1868836757.USD","SGXZ99366536.SGD","IE00BK4W5L77.USD","LU1267930730.SGD","SGXZ57979304.SGD","LU0943347566.SGD","BK4566","LU2461242641.AUD","LU2602419157.SGD","LU0820561909.HKD","LU1974910355.USD","SG9999014906.USD","LU0122379950.USD","IE00BZ1G4Q59.USD","IE0002141913.USD","LU0058720904.USD","LU0256863811.USD","LU0354030511.USD","LU1571399168.USD","LU1280957306.USD","LU1983299246.USD","LU2237438978.USD","LU1023059063.AUD","LU1804176565.USD","NVO","SG9999001176.SGD","AMGN","XLV","LU1093756168.USD","IE00BJJMRZ35.SGD","LU1712237335.SGD","NVO.AU","LLY","IBB","LU0094547139.USD","SG9999017495.SGD","LU2361044949.HKD","LU2112291526.USD","LU0868494617.USD","LU1093756325.SGD","LU2491050071.SGD","IE00B1BXHZ80.USD","IE0004445239.USD","PSTX","SG9999015978.USD","LU1917777945.USD","IE00BFTCPJ56.SGD","LU0106261372.USD"],"gpt_icon":1},{"id":"2486706970","title":"Eli Lilly, Nordisk Shares up Pre-Bell on White House Proposal to Expand Medicaid, Medicare Coverage of Weight-Loss Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2486706970","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486706970?lang=en_us&edition=fundamental","pubTime":"2024-11-26 21:16","pubTimestamp":1732626977,"startTime":"0","endTime":"0","summary":"Eli Lilly  and Novo Nordisk  shares were higher in Tuesday's premarket activity after the White House announced a proposal to expand Medicaid and Medicare coverage to include more anti-obesity indications for their popular weight loss and diabetes drugs.Shares of Eli Lilly were up nearly 4% and Novo Nordisk more than 3% in pre-bell activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0122379950.USD","LU0820561818.USD","LU0882574055.USD","LLY","LU0823416689.USD","LU0471298694.HKD","LU2264538146.SGD","IE00BFTCPJ56.SGD","LU0320765059.SGD","LU0820561909.HKD","LU1035775433.USD","NVO.AU","SG9999015978.USD","LU0672654240.SGD","LU2237438978.USD","LU1868836757.USD","SGXZ31699556.SGD","BK4533","LU2237443465.HKD","BK7104","IE00BKVL7J92.USD","LU0114720955.EUR","IE00BJJMRZ35.SGD","LU2063271972.USD","SG9999001176.SGD","NVO","LU1868836914.USD","LU1061106388.HKD","LU2265009873.SGD","GB00BDT5M118.USD","LU2237443622.USD","LU0198837287.USD","BK4007","LU0471298777.SGD","LU0109391861.USD","SG9999015986.USD","LU2491050071.SGD","LU0417517546.SGD","LU1093756168.USD","SGXZ51526630.SGD","LU2112291526.USD","IE00BZ1G4Q59.USD","BK4599","LU1064131342.USD","LU2461242641.AUD","LU2491050154.USD","IE0009355771.USD","SG9999014880.SGD","LU1983299246.USD","LU0256863811.USD"],"gpt_icon":0},{"id":"2486079497","title":"Update: Market Chatter: Eli Lilly, Novo Nordisk Press Employers to Cover the Cost of Weight-Loss Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2486079497","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486079497?lang=en_us&edition=fundamental","pubTime":"2024-11-26 20:06","pubTimestamp":1732622790,"startTime":"0","endTime":"0","summary":"(Updates with a statement from Eli Lilly in the seventh paragraph.)Eli Lilly and Company (LLY) and Novo Nordisk (NVO) are on a mission to convince employers that offering coverage to workers for weigh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2211815571.USD","SG9999013999.USD","SG9999001176.USD","IE0009355771.USD","SG9999001176.SGD","NVO","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU0354030511.USD","LU2237443622.USD","LU0672654240.SGD","SG9999014880.SGD","BK4107","IE00BJT1NW94.SGD","LU1267930730.SGD","LU2361044949.HKD","LU2237443382.USD","IE00BJJMRZ35.SGD","LU1804176565.USD","LU2602419157.SGD","LU0109391861.USD","SG9999014906.USD","BK7104","LU0882574139.USD","LU0882574055.USD","BK4516","EIG","LU0417517546.SGD","LU1814569148.SGD","LU0061475181.USD","LU1868836914.USD","LU1974910355.USD","BK4588","LU2112291526.USD","BK4533","LU1127390331.HKD","LU0689472784.USD","LU2237443549.SGD","LU1035775433.USD","LU2237438978.USD","LU2106854487.HKD","SG9999015986.USD","LLY","NVO.AU","LU1623119135.USD","LU0823416689.USD","LU0289739699.SGD","LU2324357040.USD","LU1983299246.USD","SGXZ57979304.SGD"],"gpt_icon":1},{"id":"2486078150","title":"White House Proposes Expanding Medicare, Medicaid Coverage for Anti-Obesity Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2486078150","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486078150?lang=en_us&edition=fundamental","pubTime":"2024-11-26 19:01","pubTimestamp":1732618872,"startTime":"0","endTime":"0","summary":"The White House said Tuesday it is proposing a new rule to expand coverage of anti-obesity and diabetes medications made by companies such as Novo Nordisk  and Eli Lilly  for Americans with Medicare and Medicaid.The new proposal would expand coverage that already includes diabetes and other illnesses, to include obesity, reducing out-of-pocket costs by as much as 95%, the White House said.\"This proposal would allow Americans and their doctors to determine the best path forward so they can lead healthier lives, without worrying about their ability to cover these drugs out-of-pocket, and ultimately reduce health care costs to our nation,\" the White House said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BK4W5M84.HKD","SG9999015945.SGD","IE00BKVL7J92.USD","NVO.AU","LU0471298694.HKD","BK4007","LU1983299246.USD","LU2491050071.SGD","LU1868837300.USD","LU0114720955.EUR","LU0320765059.SGD","LU1974910355.USD","LU2112291526.USD","LU1868836757.USD","BK4534","LU0823416689.USD","IE00B2B36J28.USD","BK4588","LU0203202063.USD","LU1551013342.USD","LU0417517546.SGD","IE00BFTCPJ56.SGD","LU0289739699.SGD","SG9999013999.USD","BK4585","LU0061475181.USD","LU1712237335.SGD","LLY","LU1814569148.SGD","SG9999015978.USD","SGXZ81514606.USD","LU0466842654.USD","LU2106854487.HKD","LU2602419157.SGD","LU0238689110.USD","IE0002141913.USD","LU2361044865.SGD","LU1868836914.USD","LU0385154629.USD","SG9999017495.SGD","LU1366192091.USD","IE00B1BXHZ80.USD","SGXZ31699556.SGD","LU1057294990.SGD","LU0198837287.USD","NVO","IE00B4R5TH58.HKD","LU2491049909.HKD","LU2461242641.AUD","LU1069344957.HKD"],"gpt_icon":1},{"id":"2486034983","title":"Novo Nordisk to Buy Norwegian Fish Genetics Firm Benchmark Genetics","url":"https://stock-news.laohu8.com/highlight/detail?id=2486034983","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486034983?lang=en_us&edition=fundamental","pubTime":"2024-11-26 00:25","pubTimestamp":1732551947,"startTime":"0","endTime":"0","summary":"Novo Nordisk  said Monday it has agreed to buy Benchmark Genetics, a Norwegian fish genetics company, from Benchmark Holdings for up to 260 million British pounds .Benchmark Genetics specializes in salmonid genetics, providing eggs and services to farmers in Norway, Iceland, the Faroe Islands, Chile, and other regions, Novo Nordisk said.Price: 104.49, Change: -0.57, Percent Change: -0.54","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVO.AU","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","NVO","BK7104","BK4532","BK4599","BK4585","LU1093756325.SGD","BK4007","LU0154236417.USD","BK4588","LU1093756168.USD"],"gpt_icon":1},{"id":"2486086997","title":"Market Chatter: Novo Holdings to Win EU Approval for $16.5 Billion Catalent Takeover","url":"https://stock-news.laohu8.com/highlight/detail?id=2486086997","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486086997?lang=en_us&edition=fundamental","pubTime":"2024-11-25 20:53","pubTimestamp":1732539182,"startTime":"0","endTime":"0","summary":"Novo Nordisk's  parent company, Novo Holdings, is expected to win EU antitrust approval for its pending $16.5 billion acquisition of US contract drug maker Catalent , Reuters reported Friday, citing an unnamed person with direct knowledge of the matter.The report said that Catalent is preparing senior management for the deal to go through.The deal, crucial for boosting production of Novo Nordisk's blockbuster weight-loss drug Wegovy, awaits a final decision from the European Commission by Dec. 6.Novo Nordisk, Catalent, European Commission did not immediately respond to requests for comment.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4007","NVO.AU","BK4156","BK4588","BK7104","IE00BKVL7J92.USD","CTLT","BK4599","IE00BZ1G4Q59.USD","LU1093756325.SGD","LU1093756168.USD","BK4530","NVO","BK4532","LU0154236417.USD"],"gpt_icon":0},{"id":"2485267716","title":"Viking Therapeutics a new buy at B Riley on lead obesity asset VK2735","url":"https://stock-news.laohu8.com/highlight/detail?id=2485267716","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485267716?lang=en_us&edition=fundamental","pubTime":"2024-11-22 23:20","pubTimestamp":1732288809,"startTime":"0","endTime":"0","summary":"Michail_Petrov-96/iStock via Getty Images B Riley has initiated Viking Therapeutics at buy saying that the company lead obesity treatment, VK2735, could have \"long-term disruptive potential.\" The investment bank has a $109 price target . Analyst Mayank Mamtani said that VK2735 could set itself apart from existing weight loss drugs as it is a \"GLP1/GIP agonist being developedfor an induction  and maintenance  paradigm.\"  Despite VK2735 demonstrating strong clinical results so far, the stock is down ~50% off its 52-week high, he noted, adding that upcoming \"additional visibility into manufacturing capacity and competitive positioning [could] unlock significant value through YE 2025E.\" And while Viking's drug is competing against other candidates, such as Novo Nordisk's  CagriSema, Amgen's  MariTide, and Roche's  GYM329, data updates from these programs \"represent an opportunity, in our opinion, for VK2735's unique positioning to further stand out while bringing into focus the broader por","market":"other","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/654548316/image_654548316.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/654548316/image_654548316.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4321443-viking-therapeuticsanewbuyat-b-rileyonleadobesityasset-vk-2735","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["NVO","LU0889565916.HKD","BK4599","LU0122379950.USD","AMGN","LU0154236417.USD","BK4585","IE00B4R5TH58.HKD","BK7104","LU1061106388.HKD","LU2242646821.SGD","LU1571399168.USD","IE00B2B36J28.USD","BK4566","LU1023059063.AUD","BK4588","BK4532","LU0868494617.USD","LU1093756168.USD","NVO.AU","SG9999001440.SGD","LU0109394709.USD","BK4581","IE0002141913.USD","03165","BK4533","IE00BFTCPJ56.SGD","IE00BZ1G4Q59.USD","LU0058720904.USD","LU0320765992.SGD","LU2112291526.USD","RHHBY","LU1057294990.SGD","IE00BJJMRZ35.SGD","BK4534","LU1983299246.USD","LU2242652126.USD","IE00BKVL7J92.USD","IE0009355771.USD","LU1093756325.SGD","VKTX","LU0289739699.SGD","BK4139","BK4007","IE00BJT1NW94.SGD"],"gpt_icon":1},{"id":"2485250468","title":"Novo Nordisk said to have contracted Ypsomed to make next gen obesity drug’s pens","url":"https://stock-news.laohu8.com/highlight/detail?id=2485250468","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485250468?lang=en_us&edition=fundamental","pubTime":"2024-11-22 20:31","pubTimestamp":1732278706,"startTime":"0","endTime":"0","summary":"hapabapa/iStock Editorial via Getty ImagesNovo Nordisk’s   contract with Swiss medical device maker Ypsomed  includes a deal to supply injection pens for Danish drugmaker’s next-gen obesity therapy CagriSema, Reuters reported Friday, citing a source familiar with the matter. The report indicates the company’s long-term commercial plans for the once-weekly injectable, which is currently undergoing late-stage clinical development and expected to generate Phase 3 data this year. CagriSema is designed by combining semaglutide, the active ingredient of Novo’s  popular weight loss therapy, Wegovy, with another compound mimicking a metabolic hormone called amylin. Novo  expects it to generate 25% of average weight loss within a year, compared to Wegovy’s 15% and 20% achieved by its rival weight loss therapy Zepbound developed by Eli Lilly . Spokespersons for Novo  and Ypsomed  declined to comment. Last year, Ypsomed  inked a long-term agreement to supply Novo  with autoinjectors designed to d","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4320724-novo-nordisk-contracts-ypsomed-to-make-cagrisema-pens","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["SG9999015952.SGD","LU0466842654.USD","LU1064131342.USD","LU2361045086.USD","LU0417517546.SGD","LU0256863902.USD","LU0882574139.USD","SG9999014906.USD","BK4516","SG9999015986.USD","NVO.AU","LU2361044949.HKD","LU1267930730.SGD","SG9999015945.SGD","LU2112291526.USD","LU0823416689.USD","IE00B4R5TH58.HKD","IE00BJLML261.HKD","LU1061106388.HKD","BK4533","IE00BKVL7J92.USD","LU0708995401.HKD","LU1551013425.SGD","LLY","LU2237443382.USD","LU2211815571.USD","LU0122379950.USD","LU2468319806.SGD","IE0004445239.USD","LU1551013342.USD","SG9999018857.SGD","SG9999001176.USD","LU1868837300.USD","LU0289739699.SGD","NVO","LU1366192091.USD","YPHDF","LU2089984988.USD","BK4588","SGXZ51526630.SGD","LU1868836591.USD","LU1712237335.SGD","LU1280957306.USD","LU0109391861.USD","LU0154236417.USD","IE0009355771.USD","LU1057294990.SGD","LU2491049909.HKD","NONOF","LU0354030438.USD"],"gpt_icon":1},{"id":"2485411616","title":"European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2485411616","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485411616?lang=en_us&edition=fundamental","pubTime":"2024-11-22 00:20","pubTimestamp":1732206023,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were edging down on Thursday morning, declining 0.2% to 1,309.13 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by energy company Equinor  and biotech company BioNTech , which rose 1.9% and 1.3% respectively.The decliners from continental Europe were led by pharmaceutical and chemical manufacturer Grifols  and pharmaceutical giant Novo Nordisk , which dropped 4% and 3% respectively.They were followed by telecoms and consumer electronics company Nokia , down 2.7%.From the UK and Ireland, the gainers were led by software development firm Endava  and oil and gas major Shell , which rose 5.8% and 1.3% respectively.The decliners from the UK and Ireland were led by biotech companies Silence Therapeutics  and Compass Pathways , which lost 3.1% and 2.8% respectively.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4117","BK4107","BK4020","BK4585","LU0084288595.USD","BK7104","AFG","LU1093756168.USD","IE00BMPRXR70.SGD","DAVA.AU","IE00BZ1G4Q59.USD","BK4548","LU1162221912.USD","BK4551","LU1093756325.SGD","BNTX","LU0648005311.SGD","BK4134","BK4139","DAVA","LU0300736492.USD","LU2236285917.USD","NVO.AU","BK4532","CMPS","IE00BMPRXN33.USD","LU0154236417.USD","GRFS","LU0320765646.SGD","BK4547","BK4599","NVO","LU0278409577.USD","BK4201","IE00BKVL7J92.USD","SHEL","LU0300736062.USD","BK4007","SLN","LU0098860793.USD","BK4535","NOK","BK4568","EQNR"],"gpt_icon":1},{"id":"2484125031","title":"Sector Update: Health Care Stocks Edge Higher Premarket Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2484125031","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484125031?lang=en_us&edition=fundamental","pubTime":"2024-11-20 22:18","pubTimestamp":1732112294,"startTime":"0","endTime":"0","summary":"Health care stocks were edging higher premarket Wednesday as the iShares Biotechnology ETF  was 0.4% higher and the Health Care Select Sector SPDR Fund  was recently up 0.5%.Argenx  shares were up more than 2% after the company said it will proceed with developing its experimental drug, efgartigimod subcutaneous, to treat idiopathic inflammatory myopathies in its ongoing phase 2/3 study.SAGE Therapeutics  shares were down over 5% after the company said its phase 2 DIMENSION study of dalzanemdor in participants with cognitive impairment associated with Huntington's Disease did not meet its primary and secondary endpoints.Novo Nordisk  has rolled out Wegovy in China to treat adults with obesity andoverweight, a company spokesperson confirmed to MT Newswires in an email. Novo Nordisk shares were up over 1% premarket.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4007","BK4581","NVO.AU","LU1093756168.USD","IBB","SAGE","LU0154236417.USD","BK7104","IE00BKVL7J92.USD","BK4139","LU0320765992.SGD","BK4505","NVO","BK4588","XLV","IE00BZ1G4Q59.USD","LU1093756325.SGD","ARGX","BK4532","LU0109394709.USD","LU0889565916.HKD"],"gpt_icon":1},{"id":"2484893135","title":"Novo Resources Sells Remaining Stake in Western Australia JV; Shares Up 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484893135","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484893135?lang=en_us&edition=fundamental","pubTime":"2024-11-20 10:36","pubTimestamp":1732070196,"startTime":"0","endTime":"0","summary":"Novo Resources  said Austroid Australia, a related entity of Liatam Mining, acquired the remaining 20% of the Quartz Hill joint venture in Western Australia as well as its 100% interest in gold and silver rights in the JV for AU$850,000, according to a Wednesday filing with the Australian bourse.Liatam Mining remains a 6% shareholder in Novo, the filing said.The mining firm maintains exposure to the battery metals sector through the Harding Battery Metals JV with Sociedad Química y Minera de Chile subsidiary SQM Australia, according to the filing.Novo Resources shares rose nearly 8% in afternoon trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","BK7104","BK4168","XJO.AU","XKO.AU","NVO.AU","WRN"],"gpt_icon":0},{"id":"2484900441","title":"Novo Nordisk semaglutide phase 3 trial for MASH meets primary endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2484900441","media":"seekingalpha","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484900441?lang=en_us&edition=fundamental","pubTime":"2024-11-20 07:01","pubTimestamp":1732057281,"startTime":"0","endTime":"0","summary":"Mohammed Haneefa Nizamudeen A phase 3 trial examining Novo Nordisk's  GLP-1 medicine semaglutide as a treatment for metabolic dysfunction-associated steatohepatitis  met its primary endpoints. Those endpoints were significant improvement in liver fibrosis with no worsening of steatohepatitis, and no worsening of liver fibrosis in those with MASH compared to placebo.  In the study, 2.4 mg semaglutide was given subcutaneously once a week.  Results from part 1 of the ESSENCE trial showed that at week 72, 62.9% of people treated with semaglutide achieved resolution of steatohepatitis with no worsening of liver fibrosis compared to 34.1% on placebo. Also, 37% of people treated with semaglutide 2.4 mg achieved improvements in liver fibrosis with no worsening of steatohepatitis compared to 22.5% on placebo.  A secondary endpoint found 32.8% of those on semaglutide 2.4 mg achieved both resolution of steatohepatitis with improvements in liver fibrosis vs. 16.2% of placebo patients. Semaglutide ","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1417927026/image_1417927026.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1417927026/image_1417927026.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4309561-novo-nordisksemaglutidephase-3-trialfor-mas-hmeetsprimaryendpoints","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["IE00BKVL7J92.USD","BK4532","BK4585","LU0154236417.USD","LU1093756168.USD","LU1093756325.SGD","NVO","NVO.AU","BK4007","IE00BZ1G4Q59.USD","BK7104","BK4588"],"gpt_icon":1},{"id":"2484974844","title":"Sector Update: Health Care Stocks Mixed Tuesday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2484974844","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484974844?lang=en_us&edition=fundamental","pubTime":"2024-11-20 03:09","pubTimestamp":1732043388,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed Tuesday afternoon, with the NYSE Health Care Index fractionally up and the Health Care Select Sector SPDR Fund  down 0.3%.The iShares Biotechnology ETF  rose 0.3%.In corporate news, Novo Nordisk  has launched its weight-loss drug Wegovy in China, with the first prescription to be issued at a public hospital in Shanghai this week, China-based media outlet Yicai reported Monday, citing the Danish drugmaker's official WeChat account. Novo shares popped 3.1%.Insmed  said Tuesday it terminated the sale agreement with Leerink Partners, effective Monday. Under the deal, the company agreed to offer and sell up to $500 million shares from time to time through Leerink as an agent. Insmed jumped past 9%.EnVVeno Medical  climbed 11.2% after the medical technology company said it had filed a premarket approval application with the US Food and Drug Administration for its VenoValve implants to treat severe chronic venous insufficiency.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVO","BK4581","LU0053671581.USD","INSM","LU0889565916.HKD","LU1093756325.SGD","NVNO","IBB","BK4007","BK4082","BK4585","LU0320765992.SGD","LU0154236417.USD","BK4588","BK7104","XLV","BK4139","NVO.AU","BK4532","LU0109394709.USD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU1093756168.USD"],"gpt_icon":1},{"id":"2484948789","title":"Market Chatter: Eli Lilly, Novo Nordisk Press Employers to Cover the Cost of Weight-Loss Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2484948789","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484948789?lang=en_us&edition=fundamental","pubTime":"2024-11-19 20:17","pubTimestamp":1732018645,"startTime":"0","endTime":"0","summary":"Eli Lilly and Company  and Novo Nordisk  are on a mission to convince employers that offering coverage to workers for weight-loss drugs such as Zepbound and Wegovy can save them money in the long run, The Wall Street Journal reported Tuesday.The companies say that complications from obesity are a big cost in terms of healthcare, workers' compensation and disability which can potentially be avoided, according to the report.Lilly's representatives recently targeted the New Jersey State Policemen's Benevolent Association to lay out data on the effectiveness of Zepbound, as the association has a say in designing health benefits for police and government employees, WSJ said.Many employers have opted out of paying for the drugs due to high prices of over $1,000 a month and the large eligible patient population, the report said.Currently, only about half of large employers cover anti-obesity medications, and coverage is even lesser among smaller employers, WSJ said, adding that patients must ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0640476718.USD","LU0289739699.SGD","BK4107","LU1093756325.SGD","LU0122379950.USD","LLY","LU2360106947.USD","LU1069344957.HKD","LU0256863811.USD","SG9999015952.SGD","LU0094547139.USD","LU1868836757.USD","LU1366192091.USD","LU0097036916.USD","LU0354030438.USD","SG9999018865.SGD","IE00BK4W5L77.USD","IE00BFTCPJ56.SGD","LU1974910355.USD","BK4533","LU1868836591.USD","BK4581","LU0882574139.USD","LU0256863902.USD","LU2063271972.USD","NVO.AU","SG9999014898.SGD","LU2491050154.USD","LU0114720955.EUR","LU1868837136.USD","LU2237443382.USD","IE00BZ1G4Q59.USD","LU2491049909.HKD","LU0672654240.SGD","SG9999018857.SGD","LU0471298777.SGD","BK4588","EIG","LU1267930730.SGD","LU0689472784.USD","LU0708995401.HKD","IE0002141913.USD","LU0154236417.USD","LU2264538146.SGD","NVO","LU2324357040.USD","SG9999001176.USD","IE00B1BXHZ80.USD","LU0058720904.USD","LU2461242641.AUD"],"gpt_icon":1},{"id":"2484607878","title":"Sector Update: Health Care Stocks Mixed in Afternoon Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2484607878","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484607878?lang=en_us&edition=fundamental","pubTime":"2024-11-19 02:58","pubTimestamp":1731956283,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed Monday afternoon, with the NYSE Health Care Index easing 0.1% and the Health Care Select Sector SPDR Fund  fractionally higher.The iShares Biotechnology ETF  shed 0.5%.In corporate news, CareMax  agreed to sell some of its assets as part of the healthcare provider's prearranged bankruptcy protection plan. Its shares plunged 46%.CVS Health  shares jumped 6%. The company on Monday appointed four new members to its board of directors as part of an agreement reached with activist investor Glenview Capital Management following \"productive discussions.\"US government health plans account for the majority of coverage for Eli Lilly's  Zepbound and Novo Nordisk's  Wegovy, much more than the reimbursement available from private employers and insurers, Reuters reported, citing an analysis by consulting firm Leverage. Eli Lilly shares were down 3.8% and Novo was shedding 1.9%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0203201768.USD","SG9999015952.SGD","LU0466842654.USD","BK7104","LU0072461881.USD","LU0162691827.USD","SG9999018865.SGD","LU0417517546.SGD","IE00BK4W5M84.HKD","SGXZ81514606.USD","LU2491050071.SGD","LU0320765489.SGD","LU2106854487.HKD","SG9999015978.USD","SG9999014906.USD","LU1699723380.USD","CVS","IBB","LU2461242641.AUD","CVS.AU","NVO.AU","SG9999015986.USD","LU0943347566.SGD","CMAX","IE00BJT1NW94.SGD","LU1061106388.HKD","BK4533","LLY","LU2468319806.SGD","LU1988902786.USD","LU1623119135.USD","LU0672654240.SGD","LU0079474960.USD","LU0114720955.EUR","NVO","BK4550","LU0640476718.USD","LU2089984988.USD","BK4588","SGXZ51526630.SGD","IE00BFTCPJ56.SGD","LU1712237335.SGD","LU0094547139.USD","IE00BJJMRZ35.SGD","XLV","LU0109391861.USD","LU0154236417.USD","LU0385154629.USD","LU2361044865.SGD","SG9999001176.SGD"],"gpt_icon":1},{"id":"2484983357","title":"Novo Nordisk reportedly launches Wegovy in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2484983357","media":"seekingalpha","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484983357?lang=en_us&edition=fundamental","pubTime":"2024-11-19 02:46","pubTimestamp":1731955580,"startTime":"0","endTime":"0","summary":"hapabapa/iStock Editorial via Getty Images Novo Nordisk (NVO) has reportedly launched its popular weight-loss drug Wegovy in China ahead of a rival drug by Eli Lilly (NYSE:LLY). The Danish drugmaker plans to charge $193.27 for a month's supply of the drug, which lists for around $1,349 per month","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4303757-novo-nordisk-reportedly-launches-wegovy-in-china","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["BK4516","LU1974910355.USD","LU1712237335.SGD","LU2106854487.HKD","LU2237443382.USD","LU1868836591.USD","IE00BJJMRZ35.SGD","LU1917777945.USD","LU0109391861.USD","LU2491050154.USD","LU0203201768.USD","LU1127390331.HKD","LU0385154629.USD","SGXZ31699556.SGD","LU0154236417.USD","LU1093756325.SGD","BK4007","LU2112291526.USD","LU2089984988.USD","LU0943347566.SGD","LU1093756168.USD","LU1623119135.USD","LU0079474960.USD","BK4533","LU0471298694.HKD","IE00BK4W5L77.USD","LU1814569148.SGD","LU2237443622.USD","LU1551013342.USD","NVO","LU0061475181.USD","LU0006306889.USD","LU1069344957.HKD","IE00BK4W5M84.HKD","LU2491049909.HKD","SG9999018865.SGD","NVO.AU","SGXZ99366536.SGD","LLY","LU2461242641.AUD","LU2491050071.SGD","LU0466842654.USD","LU1280957306.USD","LU0097036916.USD","IE0002141913.USD","LU0471298777.SGD","BK4585","LU2361044949.HKD","LU0820561909.HKD","LU0354030438.USD"],"gpt_icon":0},{"id":"2484603439","title":"Top Midday Stories: Spirit Airlines Files for Chapter 11 Bankruptcy Protection; Trump Team Looking to Ease Rules for Self-Driving Cars","url":"https://stock-news.laohu8.com/highlight/detail?id=2484603439","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484603439?lang=en_us&edition=fundamental","pubTime":"2024-11-19 00:54","pubTimestamp":1731948871,"startTime":"0","endTime":"0","summary":"The S&P 500 and Nasdaq Composite were both up in late-morning trading Monday, while the Dow Jones Industrial Average was about flat, as investors prepare for an earnings release from Nvidia (NVDA) lat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4534","TISI","NVDU","LU0683600562.USD","IE0034235188.USD","LU0057025933.USD","NVD2.UK","LU1642822529.SGD","2NVD.UK","LU2505996509.AUD","NVDS","LLY","NVDS.UK","SNVD.UK","LU2360107168.USD","CVS","LU0642271901.SGD","LU0471298777.SGD","F","SG9999014906.USD","LU2430703095.HKD","NVD3.UK","NVDX","LU2236285917.USD","LU1064131342.USD","LU0353189763.USD","NVDD","NVO.AU","3NVD.UK","LU0070302665.USD","BK4543","TSLA","LU0072461881.USD","CVS.AU","MFC","IE00BK4W5L77.USD","LU2213496289.HKD","LU0127658192.USD","NVD","LU0061474705.USD","NVO","SAVE.AU","LU1668664300.SGD","SG9999015986.USD","LU2430703178.SGD","NVDY","SAVE"],"gpt_icon":1}],"pageSize":20,"totalPage":8,"pageCount":7,"totalSize":146,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVO.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVO.AU\",market:\"AU\",,,undefined,":[]}}